Bausch & Lomb Corp (BLCO) Form 8-K — Oct 13, 2026
$BLCOForm 8-KItems 5.02, 7.01, 9.01Filed Oct 13, 2026, 6:09 AM ET0000950103-26-015460Original filing
Bausch + Lomb announced on October 12, 2026 that CEO Brent Saunders and the Board mutually agreed to his departure, effective immediately. Saunders also resigned from the Board, and all his outstanding equity awards, vested or unvested, were forfeited and cancelled under the separation agreement. Board Chairman Thomas J. Appio was appointed interim CEO while continuing as CEO of controlling shareholder Bausch Health.
Key figures
- Guidance
- Company expects to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D (non-GAAP) guidance; Q3 results to be reported Oct. 28.
- Attorneys fees cap usd
- 50000
- Separation payment usd
- 75500000
- Health continuation years
- 2
- Transition assistance days
- 90
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.